Scientific Reports · 2019 · 25 citations · 28 references
MedicineOncologyPharmacologyApoptosisAutophagyChemotherapyApoptosis In CancerApoptosis PharmacologyApoptosis RegulationApoptosis ResistanceAutophagy In CancerCell Cycle PharmacologyCell Cycle Arrest MechanismsEndoplasmic Reticulum StressEndoplasmic Reticulum Stress ApoptosisEndoplasmic Reticulum Stress ResponsesNeuroblastoma BiologyProteasome Inhibitor TherapyProteasome InhibitorsRefractory Neuroblastoma
Neuroblastoma is a solid malignant tumor of the sympathetic nervous system, which accounts for 8-10% of childhood cancers. Considering the overall high risk and poor prognosis associated with neuroblastoma, effective therapeutics should be developed to improve patient survival and quality of life. A recent study showed that a proteasome inhibitor, carfilzomib (CFZ), reduced cell viability of SK-N-BE(2)-M17 neuroblastoma cells. Therefore, we investigated the molecular mechanisms by which CFZ lower the cell viability of neuroblastoma cells. CFZ reduced cell viability via cell cycle arrest at G2/M and apoptosis, which involved caspase activation (caspases-8, 9, 4, and 3), endoplasmic reticulum stress, reactive oxygen species production, mitochondrial membrane potential loss, and autophagy in a dose- and time-dependent manner. The effect of CFZ was additive to that of cisplatin (Cis), a well-known chemotherapeutic drug, in terms of cell viability reduction, cell cycle arrest, and apoptosis. Importantly, the additive effect of CFZ was maintained in Cis-resistant neuroblastoma cells. These results suggest that CFZ can be used in combination therapy for patients with neuroblastoma to overcome the resistance and adverse side effects of Cis.
28
Cellular Responses to Cisplatin‐Induced DNA Damage
Alakananda Basu, Soumya Krishnamurthy · Journal of Nucleic Acids · 2010 · 570 citations · Full text